Actions

Atypical patterns of primitive marker expression in acute leukaemia

From haematologyetc.co.uk

Revision as of 18:57, 11 December 2023 by John (talk | contribs) (Created page with "<div style="width: 180px"> {| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black;" | colspan="1"''|Click to return to AML diagnosis page'' |} </div> <div style="width: 95%"> {| class="wikitable" style="border-style: solid; border-width: 5px; color:black" ! colspan="2" style = "font-size:100%; color:black"| '''Table:''' Markers primarily used t...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Table: Markers primarily used to confirm primitive nature in AML.  
The expression of some markers is typically associated with primitive cells and can help recognise the primitive nature of blast cells.
Note that these markers may also have some lineage specificity but are not generally used to assign lineage
CD45 A marker expressed by all leukocytes and their precursors. In AML expression is characteristically "weak" i.e. significantly less intense than normal lymphocytes or monocytes. In monocytic AML expression may be stronger, particular in mare mature monocytic forms where expression may resemble normal monocytes.
CD34 Frequently expressed by AML blast cells (40-80% of cases) - most often in less differentiated forms of AML. Expression is also seen frequently (and often more strongly) in ALL
CD117 Frequently expressed by AML blast cells (70-80% of cases) - where it can support myeloid differentiation, CD117 also has some value in establishing primitive differentiation as it is lost as cells mature
Other markers: In the context of a proven AML diagnosis a number of markers may be expressed that reflect the primitive nature of the cells. Some of these are more frequently associated with lymphoid disorders, but providing other criteria for AML are met they should simply be considered to show "primitivness".
These include: CD38, HLA-DR, TDT, CD7.